TR199600716A2 - Siklik yapistirici inhibitörleri. - Google Patents

Siklik yapistirici inhibitörleri.

Info

Publication number
TR199600716A2
TR199600716A2 TR96/00716A TR9600716A TR199600716A2 TR 199600716 A2 TR199600716 A2 TR 199600716A2 TR 96/00716 A TR96/00716 A TR 96/00716A TR 9600716 A TR9600716 A TR 9600716A TR 199600716 A2 TR199600716 A2 TR 199600716A2
Authority
TR
Turkey
Prior art keywords
inhibitors
cyclic
cyclic adhesive
adhesive inhibitors
adhesive
Prior art date
Application number
TR96/00716A
Other languages
English (en)
Other versions
TR199600716A3 (tr
Inventor
Alfred Dr Jonczyk
Simon Dr Goodman
Beate Dr Diefenbach
Arne Dr Sutter
Guenter Dr Hoelzemann
Horst Prof Kessler
Michael Dechantsreiter
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of TR199600716A2 publication Critical patent/TR199600716A2/tr
Publication of TR199600716A3 publication Critical patent/TR199600716A3/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR96/00716A 1995-09-15 1996-09-12 Siklik yapistirici inhibitörleri. TR199600716A2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19534177A DE19534177A1 (de) 1995-09-15 1995-09-15 Cyclische Adhäsionsinhibitoren

Publications (2)

Publication Number Publication Date
TR199600716A2 true TR199600716A2 (tr) 1997-04-22
TR199600716A3 TR199600716A3 (tr) 1997-04-22

Family

ID=7772215

Family Applications (1)

Application Number Title Priority Date Filing Date
TR96/00716A TR199600716A2 (tr) 1995-09-15 1996-09-12 Siklik yapistirici inhibitörleri.

Country Status (29)

Country Link
US (1) US6001961A (tr)
EP (1) EP0770622B1 (tr)
JP (3) JP4115550B2 (tr)
KR (1) KR100438244B1 (tr)
CN (1) CN1203090C (tr)
AR (1) AR003574A1 (tr)
AT (1) ATE189461T1 (tr)
AU (1) AU717574B2 (tr)
BR (1) BR9603751A (tr)
CA (1) CA2185489C (tr)
CO (1) CO4750841A1 (tr)
CZ (1) CZ286713B6 (tr)
DE (2) DE19534177A1 (tr)
DK (1) DK0770622T3 (tr)
ES (1) ES2144179T3 (tr)
GR (1) GR3033293T3 (tr)
HU (1) HU224614B1 (tr)
ID (1) ID18770A (tr)
MX (1) MX9604100A (tr)
NO (1) NO316946B1 (tr)
PL (1) PL185125B1 (tr)
PT (1) PT770622E (tr)
RU (1) RU2157379C2 (tr)
SI (1) SI0770622T1 (tr)
SK (1) SK282391B6 (tr)
TR (1) TR199600716A2 (tr)
TW (1) TW517064B (tr)
UA (1) UA49799C2 (tr)
ZA (1) ZA967768B (tr)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500924B1 (en) 1996-05-31 2002-12-31 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US7053041B1 (en) 1996-05-31 2006-05-30 The Scripps Research Institute Methods and compositions useful for inhibition of αvβ5mediated angiogenesis
DE19613933A1 (de) * 1996-04-06 1997-10-09 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
PL330240A1 (en) * 1996-05-31 1999-05-10 Scripps Research Inst Methods and compositions useful in inhibiting angiogenesis in which alphavbeta5 acts as intermediary
CA2252629A1 (en) * 1997-02-26 1998-09-03 Toray Industries, Inc. Remedies for hepatitis
DE19842415A1 (de) * 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
CZ20012321A3 (cs) 1998-12-23 2002-10-16 G. D. Searle & Co. Léčivo s obsahem inhibitoru cyklooxygenázy-2 a inhibitoru matricové metaloproteinázy pro kombinační terapii při léčení neoplasie
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
SK287357B6 (sk) * 1999-02-12 2010-08-09 The Scripps Research Institute Použitie antagonistu alfa v beta 3 na prípravu farmaceutickej kompozície na liečbu tumorových buniek a terapeutická kompozícia a súprava na liečenie tumoru alebo tumorových metastáz
UA71608C2 (en) * 1999-03-11 2004-12-15 Merck Patent Gmbh A method for producing the cyclic pentapeptide
MXPA01012388A (es) 1999-06-01 2002-07-30 Biogen Inc Anticuerpo monoclonal bloqueador para vla-1 y su uso para el tratamiento de trastornos inflamatorios.
US6518244B2 (en) 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
US20040029788A1 (en) * 2000-11-01 2004-02-12 Hans-Markus Bender Methods and compositions for the treatment of diseases of the eye
EP1381382B1 (en) 2000-11-01 2008-11-26 MERCK PATENT GmbH Methods and compositions for the treatment of diseases of the eye
WO2002055106A2 (en) * 2001-01-09 2002-07-18 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
UA83791C2 (ru) * 2001-04-13 2008-08-26 Байоджен Айдек Ма Инк. Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
CA2444821C (en) 2001-04-24 2012-07-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using anti-angiogenic agents and tnfa
US20050085415A1 (en) * 2002-02-14 2005-04-21 Matthias Wiesner Methods and compositions for the treatment of eye diseases
DE10228049A1 (de) * 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
CN101124240B (zh) 2003-07-18 2013-12-18 安姆根有限公司 肝细胞生长因子的特异性结合物
DE10337863A1 (de) * 2003-08-18 2005-03-17 Merck Patent Gmbh Verwendung von Chromen-4-on-Derivaten
KR101413746B1 (ko) 2005-12-22 2014-07-01 노바바이오틱스 리미티드 고리형 항균 펩타이드
US9181303B2 (en) 2005-12-22 2015-11-10 Novabiotics Limited Treatment of bacterial infections with cyclic antimicrobial peptides
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
WO2007084670A2 (en) 2006-01-18 2007-07-26 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
ES2353482T3 (es) * 2006-02-10 2011-03-02 Amgen, Inc Formas hidrato de amg706.
EP2839843B1 (en) * 2006-05-25 2018-06-20 Biogen MA Inc. VLA-1 antagonist for use in treating stroke
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
AU2008207095B2 (en) 2007-01-18 2013-08-29 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
US20080241270A1 (en) * 2007-03-30 2008-10-02 Neal Robert A Fluid composition for inhibiting surgical adhesion formation and related method of production
WO2008143933A1 (en) * 2007-05-15 2008-11-27 Cvpath Institute, Inc. Coating stents with integrin selective peptides or mimetics
DK2167128T3 (da) 2007-07-17 2012-12-03 Merck Patent Gmbh Fremstillede anti-alfa-v-integrin hybrid-antistoffer
GB0718957D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
TWI595005B (zh) 2007-08-21 2017-08-11 安健股份有限公司 人類ｃ－ｆｍｓ抗原結合蛋白質
EP2259768B1 (en) 2008-04-08 2019-05-22 Merck Patent GmbH Compositions containing cyclic peptides and methods of use
WO2010072348A1 (en) 2008-12-23 2010-07-01 Merck Patent Gmbh Biomarkers for inhibitors with anti-angiogenic activity
KR20120060947A (ko) * 2009-05-20 2012-06-12 메르크 파텐트 게엠베하 신규 고체 물질 ｛［（2ｓ,5ｒ,8ｓ,11ｓ）-5-벤질-11-（3-구아니디노-프로필）-8-이소프로필-7-메틸-3,6,9,12,15-펜타옥소-1,4,7,10,13-펜타아자-시클로펜타데크-2-일］-아세트산｝ 및 이의 제조 방법
US20120130146A1 (en) 2009-05-25 2012-05-24 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
KR20120104316A (ko) 2009-12-10 2012-09-20 메르크 파텐트 게엠베하 올리고펩티드, 바람직하게는 실렌기티드를 포함하는 약학 조성물
EP2407478A1 (en) 2010-07-14 2012-01-18 GENETADI Biotech, S.L. New cyclotetrapeptides with pro-angiogenic properties
MX2013000521A (es) 2010-07-16 2013-03-05 Merck Patent Gmbh Partido para usarse en tratamiento de cancer de mama y/o metastasis osea.
WO2012016188A2 (en) * 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012069149A1 (en) 2010-11-23 2012-05-31 Merck Patent Gmbh Solution comprising cyclic oligopeptides
TR201810294T4 (tr) 2011-02-11 2018-08-27 Merck Patent Gmbh Prostat kanseri tedavisi için anti-alfa-v integrin antikoru.
WO2012110200A1 (en) 2011-02-18 2012-08-23 Merck Patent Gmbh Cyclic peptide cyclo (l -arginyl - glycyl - l -aspartyl - d - phenylalanyl - n-methyl - l -valyl), compositions thereof, and use thereof in methods for treating graft -versus - host disease
WO2012146729A1 (en) * 2011-04-29 2012-11-01 Philipps-Universität Marburg Lasso peptides as scaffolds for peptide grafting
CA2838573A1 (en) * 2011-06-09 2012-12-13 Simon Goodman Treatment of cancers and metastases with suspensions of cilengitide in carrier
WO2013025939A2 (en) 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
US10316095B2 (en) 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US9505749B2 (en) 2012-08-29 2016-11-29 Amgen Inc. Quinazolinone compounds and derivatives thereof
HUE063437T2 (hu) 2013-09-24 2024-01-28 Fujifilm Corp Nitrogént tartalmazó vegyületet vagy sóját vagy fémkomplexét tartalmazó gyógyászati készítmény
WO2016153054A1 (ja) 2015-03-25 2016-09-29 富士フイルム株式会社 新規な含窒素化合物またはその塩の製造方法およびそれらの製造中間体
CA3002956A1 (en) * 2015-10-23 2017-04-27 Universiteit Twente Integrin binding peptides and uses thereof
JP7034914B2 (ja) 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体
EP3207937A1 (en) 2016-02-17 2017-08-23 Royal College of Surgeons in Ireland A method of treating or preventing sepsis
UA124474C2 (uk) 2016-12-22 2021-09-22 Емджен Інк. БЕНЗІЗОТІАЗОЛЬНІ, ІЗОТІАЗОЛО[3,4-b]ПІРИДИНОВІ, ХІНАЗОЛІНОВІ, ФТАЛАЗИНОВІ, ПІРИДО[2,3-d]ПІРИДАЗИНОВІ Й ПІРИДО[2,3-d]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ G12C KRAS ДЛЯ ЛІКУВАННЯ РАКУ ЛЕГЕНІ, РАКУ ПІДШЛУНКОВОЇ ЗАЛОЗИ АБО КОЛОРЕКТАЛЬНОГО РАКУ
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
IL293443A (en) 2017-09-08 2022-07-01 Amgen Inc kras g12c inhibitors and methods of using them
JP7361722B2 (ja) 2018-05-04 2023-10-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法
US11090304B2 (en) 2018-05-04 2021-08-17 Amgen Inc. KRAS G12C inhibitors and methods of using the same
CA3099045A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
JP7360396B2 (ja) 2018-06-01 2023-10-12 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法
EP4268898A3 (en) 2018-06-11 2024-01-17 Amgen Inc. Kras g12c inhibitors for treating cancer
MX2020012261A (es) 2018-06-12 2021-03-31 Amgen Inc Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
JP2020090482A (ja) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
MA55136A (fr) 2018-11-19 2022-02-23 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
MX2021007104A (es) 2018-12-20 2021-08-11 Amgen Inc Inhibidores de kif18a.
US20220002311A1 (en) 2018-12-20 2022-01-06 Amgen Inc. Kif18a inhibitors
US11236069B2 (en) 2018-12-20 2022-02-01 Amgen Inc. KIF18A inhibitors
MX2021010323A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos bicíclicos de heterociclilo y usos de este.
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms
US20220372018A1 (en) 2019-08-02 2022-11-24 Amgen Inc. Kif18a inhibitors
CN114269731A (zh) 2019-08-02 2022-04-01 美国安进公司 Kif18a抑制剂
KR20220101125A (ko) 2019-11-14 2022-07-19 암젠 인크 Kras g12c 억제제 화합물의 개선된 합성
MX2022008305A (es) 2020-01-07 2022-08-08 Revolution Medicines Inc Dosificacion de inhibidores de shp2 y metodos de tratamiento del cancer.
WO2021224234A1 (en) 2020-05-04 2021-11-11 Helmholtz-Zentrum für Infektionsforschung GmbH Antiviral use of cilengitide
EP4214209A1 (en) 2020-09-15 2023-07-26 Revolution Medicines, Inc. Indole derivatives as ras inhibitors in the treatment of cancer
JP2024512824A (ja) 2021-01-22 2024-03-19 ロイヤル カレッジ オブ サージャンズ イン アイルランド コロナウイルスの治療
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4517686A (en) * 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4589881A (en) * 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4508921A (en) * 1984-06-28 1985-04-02 Merck & Co., Inc. Process for preparation of alpha-alkyl amino acids
JP2945680B2 (ja) * 1988-09-09 1999-09-06 旭硝子株式会社 ペプチド誘導体およびその用途
DE4310643A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren

Also Published As

Publication number Publication date
NO316946B1 (no) 2004-07-05
AR003574A1 (es) 1998-08-05
CN1149588A (zh) 1997-05-14
AU717574B2 (en) 2000-03-30
ZA967768B (en) 1997-04-07
JP4115550B2 (ja) 2008-07-09
CZ264396A3 (en) 1997-04-16
EP0770622B1 (de) 2000-02-02
DE59604363D1 (de) 2000-03-09
TW517064B (en) 2003-01-11
HU224614B1 (hu) 2005-11-28
CZ286713B6 (en) 2000-06-14
SK282391B6 (sk) 2002-01-07
HU9602507D0 (en) 1996-11-28
CO4750841A1 (es) 1999-03-31
PT770622E (pt) 2000-07-31
EP0770622A3 (de) 1997-07-02
ATE189461T1 (de) 2000-02-15
GR3033293T3 (en) 2000-09-29
SK116796A3 (en) 2001-05-10
JPH09132593A (ja) 1997-05-20
CA2185489C (en) 2007-05-08
JP2007016042A (ja) 2007-01-25
DK0770622T3 (da) 2000-07-03
PL185125B1 (pl) 2003-02-28
CN1203090C (zh) 2005-05-25
ES2144179T3 (es) 2000-06-01
JP2007186525A (ja) 2007-07-26
TR199600716A3 (tr) 1997-04-22
PL316071A1 (en) 1997-03-17
UA49799C2 (uk) 2002-10-15
ID18770A (id) 1998-05-07
KR100438244B1 (ko) 2004-08-25
HUP9602507A3 (en) 1998-01-28
HUP9602507A2 (en) 1997-08-28
CA2185489A1 (en) 1997-03-16
AU6558096A (en) 1997-03-20
SI0770622T1 (en) 2000-08-31
JP4116062B2 (ja) 2008-07-09
NO963853L (no) 1997-03-17
RU2157379C2 (ru) 2000-10-10
DE19534177A1 (de) 1997-03-20
US6001961A (en) 1999-12-14
EP0770622A2 (de) 1997-05-02
KR970015598A (ko) 1997-04-28
BR9603751A (pt) 1998-06-02
NO963853D0 (no) 1996-09-13
MX9604100A (es) 1997-08-30

Similar Documents

Publication Publication Date Title
TR199600716A2 (tr) Siklik yapistirici inhibitörleri.
DE69621026D1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
DE69636353D1 (de) Datenübetragungsvorrichtung.
NL1004863A1 (nl) 5-Amino-4-ethylsulfinyl-1-arylpyrazolen.
PT858464E (pt) Inibidores de trombina
DE59708269D1 (de) Cyclische adhäsionsinhibitoren
NL1000095C2 (nl) Rolhor.
PT863916E (pt) Tripeptidos de polifluoroalquil triptofano inibidores de trombina
BR9610514A (pt) Inibidores cicloantihelmínticos
DE29506304U1 (de) Anleimungsvorrichtung
NL1000579C2 (nl) Plakbandinrichting.
ITRM950067A0 (it) Pentagramma adesivo.
ES1032948Y (es) Aplique.
FR2707481B3 (fr) Pansement adhésif.
KR960030707U (ko) 순간 접착장치
KR970703937A (ko) 금속단백질 분해효소 억제제(Metallproteinase inhibitors)
ES1038126Y (es) Pentagrama adhesivo.
ITBZ950023A0 (it) Dispositivo di cronometraggio.
ITTS950011U1 (it) R.v.t.c.
ES1032568Y (es) Protector-precinto.
IT235624Y1 (it) Portatenda.
ES1030760Y (es) Tocado-postizo.
ES1031132Y (es) Prensa-latas.
ES1031849Y (es) Tapon-grifo.
ES1030262Y (es) Porta-objetos.